CRE Research Priorities

 

You are here

CRE Research Priorities

What we are doing

  • Through this CRE ICHEAR, the research group aims to:

  • Develop a National Strategy for OM and Hearing Loss Prevention Research, focussed on Indigenous leadership, research excellence and innovation.

  • Derive better value from the substantial body of work already completed, in terms of discovery, translation and sustainability.

  •  Increase Indigenous leadership through participation as CIs, AIs and PRPs.

  • Raise awareness, advocacy and research translation.

  • Inform Australian policy and practice regarding the best strategies for further closing of the gap in social and educational disadvantage that is linked to childhood OM and hearing loss.

  • Our work has shown that:

  • Antibiotic treatments have modest clinical impacts, even under clinical trial conditions.

  • Vaccines effectively prevent infection due to the target organisms, but the diversity of pathogens is far greater than that prevented. Vaccine protection, which is dependent on multiple doses, is not effective until well after established disease.

  • Classical modifiable risk factors are very common yet there has been almost no research focussing on intervention strategies.

Our internationally recognised research team has identified new questions to be addressed through this CRE. We will focus on strategies to build Indigenous research capacity and drive research translation to make a real impact on Indigenous child health.

How?

  • Our current multidisciplinary research portfolio acknowledges the complex causal pathways to OM, and includes strategies for prevention, treatment and understanding pathogenesis via:

  • Evaluation of risk factors

  • Vaccines

  • Antibiotics for AOM and CSOM

  • Surgery

  • novel therapeutics

  • hearing loss sequelae

  • better use of data through merged datasets

Systematic reviews will synthesise research findings to date, and identify key barriers and enablers to transfer across the network of multiple stakeholder groups.

Led by a Capacity Building Group we will develop high calibre independent Indigenous researchers and national leadership. This underpins our CRE strategy

  • Innovation and expanded clinical trial capability are needed to improve prevention and treatment strategies:

  • Trials of novel antibiotic regimens are needed to enhance clinical impact.

  • Broader coverage by new vaccines to effectively prevent infection due to the diversity of pathogens causing OM.

  • Earlier schedules need to be evaluated as vaccine protection, which is dependent on multiple doses, is not effective until well after established disease.

  • Classical modifiable risk factors are very common (crowding, poor hygiene and smoke exposure), yet there has been almost no research focussing on intervention strategies.

For researchers

Otitis Media (OM), sometimes known as glue ear or runny ears…

For health practitioners

Otitis Media (OM), sometimes known as glue ear or runny ears…

For families and communities

Many Indigenous children, and almost all Indigenous children living in remote communities...